ArticleRevista da Associacao Medica Brasileira (1992)2025
A comparison of asymmetric dimethylarginine, arginine, galectin-3, and echocardiographic data with bipolar disorder and schizophrenia.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiovascular mortality in schizophrenia and bipolar disorder patients is more than double that of the general population. There appears to be a dual effect between cardiovascular diseases and schizophrenia and bipolar disorder. Inflammation and increased oxidative stress cause cardiac remodeling and increase the severity of psychiatric illness.
methodsEchocardiographic imaging was performed simultaneously with serum samples obtained for asymmetric dimethylarginine, symmetric dimethylarginine, monomethyl-L-arginine, arginine and its metabolites, and galectin 3 levels in 80 patients with bipolar disorder who were euthymic for at least 8 weeks and 69 patients with schizophrenia undergoing treatment.
resultsMonomethyl-L-arginine and arginine levels were significantly higher in bipolar disorder patients compared to schizophrenia patients. Galectin 3 level was significantly higher in bipolar disorder patients with psychotic symptoms compared to schizophrenia patients. There was no significant difference between the groups in terms of other parameters. Statistically significant differences were found between bipolar disorder and schizophrenia patients in terms of diastolic diameter (mm), systolic diameter (mm), interventricular septum (mm), left atrium (mm), and posterior wall (mm) values.
conclusionArginine and its metabolites, asymmetric dimethylarginine, symmetric dimethylarginine, and galectin 3, may be important biomarkers of cardiovascular diseases risk. In this study, changes in biochemical parameters and cardiac structure could not be explained by disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.